Welcome to our dedicated page for Eton Pharmaceuticals news (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals stock.
Eton Pharmaceuticals develops and commercializes treatments for rare diseases, with commercial products that include KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. Company news commonly covers FDA approvals, product launches, licensing of U.S. commercialization rights, specialty pharmacy distribution and Eton Cares patient-support programs.
Updates also address financial results, product-sales trends, late-stage product candidates and clinical work for rare-disease therapies. Pipeline references include Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector, with ET-700 described as an extended-release zinc acetate formulation for Wilson disease.
Eton Pharmaceuticals, Inc. will report its first quarter 2024 financial results on May 9, 2024. The company focuses on developing treatments for rare diseases. A conference call and webcast will discuss the results at 4:30 p.m. ET on the same day. Investors can email questions or access the webcast on Eton's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.